

REVIEW

Comorbidities/Intervention

Nutritional strategies to attenuate postprandial glycemic response

Kenneth Pasmans  | Ruth C. R. Meex  | Luc J. C. van Loon  | Ellen E. Blaak 

Department of Human Biology, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands

Correspondence

Ellen E. Blaak, Department of Human Biology, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands.
Email: e.blaak@maastrichtuniversity.nl

Summary

Maintaining good glycemic control to prevent complications is crucial in people with type 2 diabetes and in people with prediabetes and in the general population. Different strategies to improve glycemic control involve the prescription of blood glucose-lowering drugs and the modulation of physical activity and diet. Interestingly, lifestyle intervention may be more effective in lowering hyperglycemia than pharmaceutical intervention. Regulation of postprandial glycemia is complex, but specific nutritional strategies can be applied to attenuate postprandial hyperglycemia. These strategies include reducing total carbohydrate intake, consuming carbohydrates with a lower glycemic index, the addition of or substitution by sweeteners and fibers, using food compounds which delay or inhibit gastric emptying or carbohydrate digestion, and using food compounds which inhibit intestinal glucose absorption. Nevertheless, it must be noted that every individual may respond differently to certain nutritional interventions. Therefore, a personalized approach is of importance to choose the optimal nutritional strategy to improve postprandial glycemia for each individual, but this requires a better understanding of the mechanisms explaining the differential responses between individuals.

KEYWORDS

dietary fiber, postprandial hyperglycemia, type 2 diabetes, α -glucosidase inhibitor

1 | INTRODUCTION

Glycemic variability is a predictor of premature mortality in the general population, in people with prediabetes, and in people with type 2 diabetes (T2D).^{1,2} It is crucial to maintain good glycemic control in order to prevent the development of cardiometabolic diseases.³ There are different strategies that can be applied to improve glycemic

control. Besides dietary and lifestyle advices, the majority of patients with T2D are treated with blood glucose-lowering drugs. This includes drugs that improve insulin sensitivity in liver, adipose tissue, and skeletal muscle; drugs that increase insulin secretion of the pancreas; drugs that extend the duration of activity of the so-called satiety hormones gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1); and drugs that inhibit glucose reabsorption from the kidneys, thereby resulting in excretion of glucose via urine.

In the case of hyperglycemia in the absence of diabetes, lifestyle intervention, focused on diet and physical activity to improve glycemic control, was associated with a $\pm 50\%$ reduced risk of developing

Abbreviations: BMI, body mass index; CHO, carbohydrate; GI, glycemic index; GIP, gastric inhibitory polypeptide; GL, glycemic load; GLP-1, glucagon-like peptide-1; GLUT2, glucose transporter 2; HbA_{1c}, glycated hemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance; SGLT1, sodium-glucose cotransporter 1; T2D, type 2 diabetes.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *Obesity Reviews* published by John Wiley & Sons Ltd on behalf of World Obesity Federation.

diabetes.^{4,5} Indeed, modulation of diet and exercise may improve whole-body insulin sensitivity, and some studies actually report that lifestyle intervention can be more effective in lowering hyperglycemia than the use of drugs.^{6,7} As dietary carbohydrate (CHO) is the main dietary component affecting glycemia, many intervention studies that are described involve the effects of CHOs, including concepts like glycemic index (GI) and glycemic load (GL),³ as described more extensively below. Nutritional strategies aimed at inhibiting CHO digestion and glucose absorption in the small intestine have been developed. Inhibition of CHO digestion and absorption leads to a delayed glucose appearance in the circulation, thereby decreasing postprandial hyperglycemia. The aim of this review is to give an overview of the determinants of postprandial glycemia related to diet composition, digestion, and absorption. We will discuss nutritional strategies that can be applied to inhibit the pace of digestion and absorption in order to ameliorate the postprandial glycemic response.

2 | REGULATION OF POSTPRANDIAL GLYCEMIA

The blood glucose concentration reflects the balance between glucose appearance and glucose disposal. In the fasted condition, no exogenous glucose enters the circulation and so glucose appearance is only influenced by metabolic processes in the body. The pancreas secretes glucagon and reduces insulin secretion when blood glucose concentrations are low, which promotes gluconeogenesis and glycogenolysis in the liver. In the postprandial state, glucose appearance is heavily influenced by the amount and composition of the food consumed, in particular dietary CHOs, and by the pace of food digestion and absorption. Blood glucose disposal, on the other hand, is strongly affected by whole-body insulin sensitivity and insulin secretion. Stimulation of insulin secretion, for instance by protein or amino acid ingestion, can also be considered to improve glycemic control.^{8,9} However, such strategies to increase glucose disposal fall outside the scope of this review. Interestingly, stable isotope methodologies have made it possible to calculate how much exogenous glucose appearance contributes to postprandial glycemia in addition to endogenous glucose production.¹⁰ These studies provide useful insight into the effects of specific CHO-containing products on postprandial glucose metabolism. For instance, the oral glucose tolerance test, which is used to measure the state of glucose tolerance of individuals, can be enriched with ¹³C-glucose or [6,6-²H₂]-glucose tracers to obtain information on postprandial glucose handling in different metabolic subgroups, such as people with normal glucose tolerance, impaired glucose tolerance, and impaired fasting glucose. Such a study revealed that the blood glucose pool in people with normal glucose tolerance consists of 90% exogenous glucose and 10% endogenous glucose 120 min after ingestion of the 75-g glucose load.¹¹ Additionally, people with impaired fasting glucose showed a similar postprandial glucose handling as compared to people with normal glucose tolerance, whereas people with impaired glucose tolerance showed substantially higher absolute exogenous glucose concentrations.¹¹ Similar tests may be performed to measure the rate of exogenous glucose appearance, endogenous

glucose production, and glucose disposal rate after ingestion of numerous other food and drink products, such as bread or a sucrose drink, or mixed meals.^{12,13}

2.1 | Glycemic index and glycemic load

The UK Scientific Advisory Committee on Nutrition recommends a reference intake of 50 E% of CHOs for the population on average.¹⁴ This makes CHOs quantitatively the most important energy source for the body. CHOs are composed of one or more saccharide molecules, and depending on their structure, digestible CHOs can be divided into four main categories, namely, monosaccharides, disaccharides, oligosaccharides, and polysaccharides. Importantly, digestible polysaccharides such as starches can influence postprandial glycemia directly, whereas nondigestible polysaccharides such as dietary fibers can influence postprandial glycemia more indirectly via interference with macronutrient absorption or microbial composition.

The concept of GI has been introduced to obtain a better classification of the health effects of CHOs beyond their chemical structure. GI is a numerical index on a scale of 0 to 100 and is used to indicate the potential of CHO-containing foods to increase blood glucose concentrations. For reference purposes, glucose is assigned the maximum value of 100. High-GI foods, which have a GI \geq 70, can raise blood glucose concentrations more than low-GI foods, which have a GI \leq 55.¹⁵ Apart from GI, also GL is used to indicate the potential of food to increase blood glucose concentrations. However, in contrast to GI, GL also takes the total available CHO content of a certain amount of food into account.¹⁵ It is therefore evident that the quantity of glycemic CHOs consumed, together with the relative ease by which those CHOs can be digested, both have a direct effect on postprandial glycemia. An enormous amount of research has been performed on elucidating the connection between CHO intake and numerous health outcomes. A series of systematic reviews and meta-analyses of studies in the general population showed that low-GI diets were associated with a reduced stroke mortality compared with high-GI diets.¹⁶ In addition, it was found that low-GI diets effectively reduced glycated hemoglobin (HbA_{1c}), fasting glucose, body mass index (BMI), total cholesterol, and low-density lipoprotein in people with type 1 diabetes, T2D, and impaired glucose tolerance.¹⁷ In line with this, a recent meta-analysis which included prospective cohort studies with up to 26 years of follow-up found there was strong evidence for a causal effect of GI and GL on the risk of T2D.¹⁸ Furthermore, consumption of low-GI foods and limiting the GL of meals improved glycemic control in patients with T2D, and possibly people with a normal glucose tolerance.¹⁹ However, there was no effect on fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), high-density lipoprotein, triglycerides, and insulin requirements.¹⁷ Communicating available information on GI and GL to the general public for health benefits has been stressed internationally,¹⁵ but there are some limitations. Indeed, only a certain number of food items have officially tested GI values, most of which are for American and Australian food products. Furthermore, the number of participants used to test the GI of specific food items is often limited, and epidemiological nutritional

studies estimate long-term intakes for individual participants by using dietary questionnaires which are not optimally designed and also not validated for dietary GI and GL.^{20,21} In addition to this, it is also very difficult to tease out the effects of postprandial glucose per se, because it is accompanied by elevated fasting blood glucose concentrations, and postprandial hyperlipidemia and hyperinsulinemia.²² Especially the magnitude of the reduction in acute postprandial glucose exposure needed to achieve long-term metabolic health effects is currently unknown. A recent systematic review and meta-analysis of dietary intervention studies in relation to postprandial hyperglycemia showed that only a small heterogeneous set of dietary intervention studies are available where postprandial glucose was measured, and that more dietary intervention studies are needed.²² Additionally, the authors of a recent systematic review and meta-analysis describing the effects of α -glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses, were able to quantify clinically relevant estimates for a reduction in postprandial glucose per se, also for individuals without diabetes.⁵ This meta-analysis indicates that a relative reduction of acute incremental postprandial glucose of ± 45 –50% (0.5 mmol/L in people without diabetes and 1.5 mmol/L in people with diabetes) can be seen as a clinically relevant reference point for reducing postprandial glucose concentrations via pharmaceutical and lifestyle interventions in the long term.⁵

2.2 | Strategies to reduce glycemic index and glycemic load

There are several nutritional strategies that can be used to reduce the GI and GL of the diet, thereby attenuating postprandial hyperglycemia. It is possible to simply limit the amount of glycemic CHOs in the diet or specific food products, but that comes at the expense of sweetness. Sweeteners, on the other hand, work well as a replacement for glucose or sucrose to lower postprandial glycemia, without affecting the sweetness of the product. Fructose is considered to be a naturally occurring caloric sweetener. A replacement of 67% sucrose by fructose showed lower values for the incremental area under the curve of glucose from 0 to 120 min compared with a 50% replacement, a 33% replacement, or no replacement at all.²³ This has prompted the European Food Safety Authority and the European Commission to approve the health claim that the replacement of sucrose and/or glucose by fructose lowers postprandial glycemia. Apart from fructose, there is also a wide variety of non-nutritive, low-energy or otherwise alternative artificial and plant-derived sweeteners available to reduce postprandial glycemia, such as stevia, aspartame, trehalose, and isomaltulose. Studies in which several of these sweeteners have been investigated are reviewed elsewhere.^{24,25} Trehalose is a less commonly occurring disaccharide consisting of two glucose molecules linked together in a different way compared with the disaccharide maltose. Trehalose and maltose both provide approximately 4 kcal/g consumed, but trehalose contains an α -1,1-glycosidic bond, whereas maltose contains an α -1,4-glycosidic bond. Isomaltulose is a less commonly occurring disaccharide consisting of one glucose

molecule plus one fructose molecule linked together in a different way compared with the disaccharide sucrose. Isomaltulose and sucrose also provide 4 kcal/g consumed, but isomaltulose contains an α -1,6-glycosidic bond, whereas sucrose contains an α -1,2-glycosidic bond. Both trehalose and isomaltulose were found to reduce glycemic and insulinemic responses in individuals who were overweight and had glucose intolerance, as well as in healthy individuals.^{26–30} Also other studies found beneficial effects for isomaltulose when compared with sucrose.^{31–33} These results clearly show the possibility to reduce the dietary intake of glycemic CHOs by replacing them with sweeteners or other structurally manipulated CHOs, at least in the short term. Additionally, a meta-analysis of human intervention studies supports the use of low-energy sweeteners in weight management, constrained primarily by the amount of added sugar that those sweeteners can displace in the diet.³⁴ Notably, for artificial sweeteners, adverse health effects on microbial composition and glycemic control have also been reported, but data are not consistent,^{24,25,35} and could not be confirmed in a meta-analysis of human studies.³⁶ More studies will be needed to investigate the possible impact of sweeteners on certain determinants of metabolic health.²⁵

2.3 | Health effects of dietary fibers

Dietary fibers are indigestible CHOs, containing a heterogeneous group of compounds, which are an important component of a healthy diet. Systematic reviews and meta-analyses have shown that total fiber intake reduces T2D risk³⁷ and incidence in a dose-response dependent manner.¹⁶ Additionally, a systematic review and meta-analyses to analyze the effects of total dietary fiber intake on glycemic control and cardiometabolic risk factors in people with prediabetes, type 1 diabetes, and T2D showed a dose-response relationship between fiber intake and reduction in HbA_{1c}, fasting plasma glucose, insulin, and HOMA-IR.³⁸ In line, a meta-analysis of randomized controlled trials showed that microbiota-accessible CHOs improved glycemic control, blood lipid, body weight, and inflammatory markers for people with T2D.³⁹ Due to their health effects, in many countries, it is recommended to increase total fiber intake to 25–35 g per day for adults. Current fiber intake is only ± 20 g per day on average.³⁹ Overall, it is recommended to consume more whole grains as a way to increase fiber intake.^{16,38,40}

Despite the above evidence, well-controlled long-term human intervention studies are not always consistent with respect to effects of specific fibers on T2D and cardiometabolic risk.⁴¹ This emphasizes the heterogeneity of compounds which vastly differ in water solubility, viscosity, binding and bulking ability, and fermentability, and also vary in their effects on host metabolism and cardiometabolic health.^{41,42} The properties of different fibers in relation to health effects are discussed extensively elsewhere.^{39,41–47} Below, the effects of prebiotic fibers (fermented by gut microbiota), insoluble fibers, and viscous soluble fibers will be discussed; the latter in the context of nutritional strategies to reduce gastric emptying.

2.3.1 | Health effects of prebiotic fibers

Prebiotic fibers exert their health effects because they are fermented specifically by the gut microbiota, thereby allowing beneficial microorganisms to increase in number. In people with T2D, dietary fiber consumption in general has been shown to improve HbA_{1C} and BMI by modulating the gut microbiota composition.^{48,49} Inulin-type fructans are nonviscous soluble fibers and have prebiotic properties, which are beneficial for blood glucose regulation.⁵⁰ A recent systematic review and meta-analysis revealed that longer-term supplementation with inulin-type fructans improves glycemic control in people with prediabetes and T2D.⁵¹ Both inulin and oligofructose are examples of inulin-type fructans. Longer-term supplementation with inulin may increase the relative abundance of bifidobacteria, which is a possible underlying mechanism of the beneficial metabolic effects seen in such studies.⁵² In addition to their prebiotic properties, the nonviscous soluble fibers fructans have an intrinsic sweetness, which may also make them suitable in an acute setting to partially replace glycemic CHOs in food. It was found that 20% replacement of sucrose by oligofructose in a yoghurt drink, as well as 30% replacement of sucrose by inulin in a fruit jelly both resulted in reduced glycemic and insulinemic responses in healthy adults compared with the full-sugar variants.⁵³

2.3.2 | Health effects of insoluble fibers

Insoluble fibers, which include wheat bran and cellulose, do not dissolve in water, and mostly contribute to fecal bulking.^{41,43} Foods containing whole grains are rich in insoluble fibers, and are associated with a decreased risk of developing T2D, as indicated by several meta-analyses.^{16,40} The underlying mechanisms may relate to interference with nutrient absorption, alterations in gastrointestinal transit time, and effects on the gut microbiota composition.⁴¹

2.4 | Nutritional strategies to reduce gastric emptying

Gastric emptying has a major influence on glycemia by allowing further digestion of disaccharides and polysaccharides, as well as the absorption of glucose in the small intestine. Reducing the rate of gastric emptying will lead to reduced postprandial glucose concentrations, at least in the early postprandial phase for people without or with T2D.^{54–56} In the early 1990s, it has been estimated that gastric emptying after the ingestion of 75 g of glucose dissolved in water accounts for approximately 34% of the variance in peak plasma glucose concentration.⁵⁷ The mechanisms that regulate gastric emptying rate are highly complex,⁵⁸ and involve control by multiple hormones, including ghrelin, cholecystokinin, GLP-1, and peptide YY.⁵⁹ Ghrelin stimulates gastric emptying, whereas cholecystokinin, GLP-1, and peptide YY inhibit gastric emptying. Furthermore, as a bidirectional feedback response to prevent excessive blood glucose fluctuations, gastric emptying is inhibited by hyperglycemia and stimulated by

hypoglycemia.⁶⁰ In healthy participants, mean gastric emptying time after a meal was found to be approximately 3.5 h,⁶¹ whereas in individuals with T2D, both a reduced gastric emptying rate and an increased gastric emptying rate have been found.^{62,63} One of the explanations for the variation in gastric emptying in diabetes may relate to the fact that hyperglycemia and hypoglycemia are both common in individuals with T2D, thereby having opposite effects on gastric emptying rate via hormonal feedback. Another aspect of interest is that solid and liquid meals can also differentially affect gastric emptying rate.⁶⁴ It has been shown that consumption of CHOs as liquids leads to substantially higher postprandial glycemic responses than consumption of CHOs as solid food,⁶⁵ although it is the digestibility of CHOs that has the largest influence on postprandial glucose concentrations.⁶⁶

Nutritional strategies to slow down the rate of gastric emptying, thereby attenuating the postprandial glycemic response, include co-ingestion of glycemic CHOs with other macronutrients such as fat and protein.^{67–69} In a randomized crossover study, men with T2D ingested water before a mashed potato meal, oil before a mashed potato meal, or water before a mashed potato meal that contained oil. From that study, it was clear that fat—in this case the oil—slowed down gastric emptying and reduced postprandial glycemic and insulinemic responses compared with water.⁷⁰ In another study involving people with T2D, a whey protein preload slowed down gastric emptying and reduced postprandial glycemic response after a potato meal compared with the condition in which no whey protein was consumed with the meal, as well as compared with the condition where whey protein was ingested as part of the potato meal.⁷¹

In addition to fat and protein, consumption of (viscous) dietary fiber can also slow down the rate of gastric emptying.⁷² Viscous soluble fibers, which include β -glucan, psyllium, pectin, and raw guar gum, have the characteristic that they can form gel-like structures, thereby influencing gastric emptying and further digestion of nutrients. Regarding acute effects on gastric emptying, one study measured the impact of guar gum and chickpea flour, which has a high fiber content, added to wheat-based flatbreads on postprandial glucose kinetics in healthy males, and found that these reduced postprandial glucose and insulin concentrations compared with the control flatbread.⁷³ It was also shown in men and women without diabetes that the ingestion of a meal containing β -glucan resulted in reduced glycemic and insulinemic responses as well as a delayed gastric-emptying half-time compared with a β -glucan-free control meal, which had the same macronutrient and energy content.⁷⁴ The conclusion of a recent systematic review and meta-analysis on oat β -glucan was that there is strong evidence that the addition of oat β -glucan to CHO-containing meals attenuates glycemic and insulinemic responses.⁷⁵ Psyllium was also shown to delay gastric emptying,⁷⁶ and to attenuate the glycemic response when added to a meal.⁷⁷ Longer-term supplementation with viscous soluble fiber psyllium has been shown to reduce fasting blood glucose and HbA_{1C}.⁷⁸ A systematic review and meta-analysis of viscous soluble fiber supplementation in patients with T2D showed that longer-term supplementation improves markers of glycemic control, such as HbA_{1C}, fasting glucose, and HOMA-IR.⁷⁹ The mechanisms

linking the effects on acute postprandial glycemic response to longer-term improvements in glycemic control in people with T2D, are not fully elucidated.

2.5 | Rate of carbohydrate digestion in the small intestine

The rate of glucose appearance in plasma is directly dependent on the small intestinal transit time, on the amount of glucose that is present in the different segments of the small intestine at a given time, and on the affinity of the intestinal glucose transporter.⁸⁰ Several studies have shown that small intestinal transit in healthy participants is completed within a few hours after consuming a meal,⁸¹ approximately 4.5 h in total on average.⁶¹ Nevertheless, there are major inter-individual differences in whole-gut transit time, depending on sex, age, and the country of residence.⁶¹ Increasing age was associated with a shorter gastric emptying time, but a longer small bowel transit time plus colonic transit time.⁶¹ The female sex was associated with a longer gastric emptying time, and small bowel transit time plus colonic transit time.⁶¹ In a recent study, researchers provided a labeled mixed meal to lean participants and participants with morbid obesity, and investigated the rate of gastric emptying and the small intestinal transit time. Whereas the gastric emptying and small intestinal transit were slower, and postprandial glucose absorption was reduced in the participants with obesity compared with the lean participants, overall postprandial glucose was higher.⁸² These findings can be explained due to increased fasting glucose concentrations and decreased insulin sensitivity in the participants with obesity compared with the lean participants.⁸²

One widely used approach to reduce postprandial glucose concentrations is by inhibiting digestion of CHOs, thereby inhibiting intestinal glucose uptake. CHO digestion is regulated by a number of enzymes at several locations across the digestive tract. Disaccharides, which are either ingested or produced during the digestion of polysaccharides, are hydrolyzed to monosaccharides by different disaccharidases.⁸³ These disaccharidases are brush-border enzymes located in the intestinal epithelium. Pharmacological α -glucosidase inhibitors are widely prescribed to patients with T2D to reduce postprandial hyperglycemia, either as a monotherapy or in combination with other anti-diabetic drugs,⁸⁴ and they are also used by people without diabetes in order to prevent the development of diabetes, generally attenuating an increase in acute postprandial glucose by ± 45 –50% in both groups.⁵ The α -glucosidase inhibitor acarbose has been shown to be effective in reducing postprandial hyperglycemia in patients with T2D.⁸⁵ However, gastrointestinal side effects such as flatulence, soft stools, and abdominal discomfort have been reported,^{85,86} and therefore, the search for additional synthetic α -glucosidase inhibitors is ongoing.⁸⁷ Numerous alternative compounds with possibly superior α -glucosidase inhibitory profiles isolated from plant sources have also been reported, many of which belong to the class of phenolic compounds, but these were mainly investigated *in vitro*.^{88,89} Phenolic compounds are a class of organic molecules in which one or more

hydroxyl groups are directly linked to an aromatic ring. Polyphenols are compounds which have multiple phenol units. Flavonoids form the largest class of compounds within the family of polyphenols, which also consists of the classes of phenolic acids and lignans. Anthocyanins are a well-known example within the class of flavonoids. Many plants produce phenolic or polyphenolic compounds, prompting numerous studies in which the effects of polyphenol-containing fruits and berries on intestinal CHO digestion are investigated.

Blackcurrants, apples, red grapes, cinnamon, and blueberries are examples of plant components found to contain anthocyanin and/or procyanidin.^{90–92} When blackcurrant extract containing 600-mg anthocyanins was consumed by men and postmenopausal women immediately before a high-CHO meal, it resulted in lower glucose and insulin concentrations in the early postprandial period up to 30 min compared with the control without blackcurrant extract, and in lower GLP-1 and GIP concentrations in the later postprandial period up to 90 or 120 min.⁹² This has been suggested to be caused, at least partly, by the inhibitory effects of the anthocyanins and other polyphenols in the drinks on pancreatic α -amylase and intestinal α -glucosidase activity. In a different study, apple, red grape, and cinnamon were found to inhibit α -glucosidase, α -amylase, and lipase in an *in vitro* model resembling the human gastrointestinal system.⁹¹ In yet another study, an optimization process was investigated for the extraction of components from grape seeds, which led to a higher inhibition of α -glucosidase and α -amylase than acarbose *in vitro*.⁹³ Finally, a study in young adults showed a beneficial postprandial glycemic response after ingestion of blueberry powder rich in anthocyanins compared with a sugar-matched control without blueberry anthocyanins.⁹⁰ Importantly, it must be noted in the case of polyphenols that the mechanism of action in attenuating increases in postprandial glucose can extend much further than α -glucosidase inhibitory activity alone.

Besides the phenolic compounds described above, there are other compounds which can have similar inhibitory effects on CHO-digesting enzymes, such as L-arabinose, D-sorbose, a milk protein hydrolysate, and inulin-type fructans. L-arabinose is a low-calorie pentose, and therefore a monosaccharide, with sweetener properties. It is a substantial component of plant cell wall polysaccharides. *In vitro* studies showed that L-arabinose acts as a specific α -glucosidase inhibitor to target the activity of sucrase in an uncompetitive manner, but not the activity of other glycoside hydrolases.⁹⁴ L-arabinose can remain bound to the sucrase-sucrose complex for up to several hours,⁹⁵ preventing the hydrolysis of sucrose to glucose and fructose. In healthy participants^{96,97} and people with T2D,⁹⁷ it was found that L-arabinose co-ingestion can limit sucrose beverage-induced increases in blood glucose concentrations acutely. Importantly though, excessive inhibition of sucrase can lead to an accumulation of undigested sugars in the small intestine, resulting in major clinical consequences such as diarrhea and abdominal pain.⁹⁸ One study reported gastrointestinal symptoms after ingestion of 75 g sucrose combined with either 1-, 2-, or 3-g L-arabinose,⁹⁶ whereas this was not the case in another study after ingestion of 50 g sucrose combined with 2-g L-arabinose.⁹⁷ A different compound, D-sorbose, an artificially created isomer of the naturally occurring monosaccharide L-sorbose, was also

found to inhibit disaccharidases in rats, thereby attenuating postprandial increases in blood glucose and insulin concentrations.⁹⁹ The same authors also demonstrated that rat intestinal enzymes are a suitable substitute for human enzymes when testing the inhibitory effects of compounds on disaccharidases.¹⁰⁰ Furthermore, a milk protein hydrolysate with an inhibitory effect on α -glucosidase activity showed reduced postprandial glucose concentrations compared with placebo in participants with prediabetes, and decreased HbA_{1c}.¹⁰¹ Finally, in a mouse model, it has also been shown that inulin-type fructans from chicory have a direct inhibitory effect on sucrase activity.¹⁰² Those mice were fed a diet supplemented with an inulin extract for 3 weeks, after which the jejunal mucosa was taken and tested *in vitro*. The investigators observed that the ability to hydrolyze sucrose into glucose was significantly reduced in the mice that received the diet supplemented with inulin, compared with the group of mice fed a standard diet.¹⁰² These studies show that reducing digestion of sucrose is a suitable strategy to target hyperglycemia, although the number of human studies is limited relative to the number of *in vitro* and rodent studies.

2.6 | Carbohydrate uptake in the small intestine

Glucose uptake over the intestinal membrane is regulated by several intestinal glucose transporters. At the apical membrane of the small intestinal epithelial cells, the sodium-glucose cotransporter 1 (SGLT1) uses the Na⁺ gradient across the membrane to actively transport glucose and galactose into the epithelial cells, whereas fructose diffuses passively into epithelial cells via GLUT5. At the basolateral membrane, glucose, galactose, and fructose passively diffuse into the bloodstream via glucose transporter 2 (GLUT2). Influencing these processes can result in beneficial effects on postprandial glycemia. In lean participants, GLUT2 has not been found on the apical membrane.¹⁰³ In participants with morbid obesity and insulin resistance, however, GLUT2 has been shown to accumulate in the apical membrane of jejunal enterocytes and this allowed glucose to passively diffuse into the bloodstream.¹⁰³ The inhibitory effects of polyphenols on SGLT1 and GLUT2 have been investigated mainly in Caco-2 cells as an *in vitro* model of human enterocytes.¹⁰⁴ *In vitro* studies showed that sappanin-type homoisoflavonoids and the flavonoids quercetin and isoquercitrin noncompetitively inhibit GLUT2, thereby preventing the uptake of glucose.^{105,106} In support of this, also an *in vivo* study in healthy men and women demonstrated that the flavonoid hesperidin decreased the postprandial glycemic response to orange juice via inhibition of GLUT2.¹⁰⁷ Apple and blackcurrant polyphenol-rich drinks lowered postprandial glucose concentrations in healthy men and postmenopausal women.¹⁰⁸ Both apple and blackcurrant polyphenols reduced total and GLUT-mediated glucose uptake *in vitro* in Caco-2 cells.¹⁰⁸ For other polyphenols and phenolic acids extracted from strawberries and apples, it was also found that they can inhibit SGLT1 and/or GLUT2 *in vitro*.¹⁰⁹ Interestingly, berry flavonoids may not only inhibit the glucose transporters, but they may also decrease the expression of those transporters in Caco-2 cells.¹¹⁰ This additional

characteristic may make phenolic compounds exceptionally beneficial for attenuating postprandial glycemic responses in humans. Available information and controversies about inhibition of glucose transporters by phenolic compounds have been reviewed elsewhere.¹¹¹ Overall, the beneficial effects of polyphenols on postprandial glycemic response may be a combination of the α -glucosidase inhibitory qualities described earlier, as well as the glucose transporter inhibitory qualities.¹¹² Interestingly, the effects of polyphenols are not limited to the two mechanisms which we have described. Other mechanisms may include effects on gut microbiota composition, mitochondrial function, substrate utilization, and lipolysis.^{113,114}

3 | INTERINDIVIDUAL DIFFERENCES IN POSTPRANDIAL GLYCEMIC RESPONSE

It has become clear that there is a high interindividual variability in the glycemic response to certain foods. To elucidate individual differences in postprandial glycemic response, Zeevi et al. developed a model which predicts the response to certain types of food with the use of a machine-learning algorithm that integrates blood parameters, dietary habits, anthropometrics, physical activity status, and gut microbiota composition.¹¹⁵ The model was initially developed for a heterogeneous Israeli population consisting of both men and women with a BMI ranging from normal to obese, and with a state of glucose tolerance ranging from normal to T2D.¹¹⁵ Later on, it was also found to be applicable to a Midwestern American population without diabetes,^{116,117} suggesting that the model might be valuable for other populations as well. Large interindividual variability in glycemic responses to standardized meals was also found by another study, which allowed the authors to identify so-called “glucotypes”, which is a form of classification that can place individuals into clinically relevant subgroups based on absolute amount of glucose variability and the fraction of time spent in low, moderate, or high variability.¹¹⁸ Yet another study, the PREDICT 1 study, also showed a high interindividual variability in postprandial glycemic response to identical meals, and this study is currently being followed-up in order to better understand individual responses to food.¹¹⁹ Indeed, personalized approaches require an understanding of the mechanisms explaining differential responses in order to be reproducible and translated into treatment strategies and guidelines.

4 | CONCLUSION AND FUTURE DIRECTIONS

Good glycemic control is crucial to maintain health and to prevent disease.³ This is the case in people with T2D, but large fluctuations in glycemia should also be avoided in healthy individuals and individuals with prediabetes. There are different strategies that can be applied to attenuate postprandial glycemia, including pharmacological and nutritional strategies as well as exercise. This review discussed the main determinants of postprandial glycemic response, and nutritional

strategies to attenuate that response. Postprandial glycemic response is the combined result of several key aspects and processes, namely the total amount of ingested CHOs, the structural properties of the ingested CHOs, the rate of gastric emptying, the rate of CHO digestion, and the rate of glucose absorption in the small intestine. Nutritional strategies to attenuate postprandial glycemic response include reducing the amount of ingested CHOs, consuming CHOs with a lower GI, the addition of or substitution by sweeteners and fibers, using food compounds which delay or inhibit gastric emptying or CHO digestion, and using food compounds which inhibit intestinal glucose absorption.

Apart from nutritional and physical determinants, there also seem to be additional factors that influence glycemia. In general, the timing of food intake and how that may affect glycemic and metabolic responses has become a hot topic, with studies demonstrating that both high-GI and low-GI meals increase postprandial glucose concentrations more at dinner than at breakfast.^{120,121} This points towards a possible role for the circadian rhythm in the regulation of glycemia. The complex process of regulation of glucose metabolism by the circadian functions falls outside the scope of this review and has been reviewed elsewhere.¹²²

Overall, it can be concluded that there are several nutritional strategies available to achieve an attenuation in postprandial glycemia. Despite the availability of such strategies, it must be noted that there are individual or subgroup-based responses to certain types of food, so a personalized approach is of importance to choose the optimal nutritional strategy to improve postprandial glycemia for every individual.

ACKNOWLEDGMENT

None.

CONFLICT OF INTEREST

KP has received funding for conducting a study involving L-arabinose from Sensus B.V. (Royal Cosun). LvL has received research grants, consulting fees, and speaking honoraria for work on postprandial muscle metabolism; a full overview is provided at <https://www.maastrichtuniversity.nl/l.vanloon>. RM and EB have no conflict of interest to declare.

AUTHOR CONTRIBUTIONS

KP wrote the manuscript. RM and EB conceptualized the manuscript. KP, RM, and EB discussed the content. RM, LvL, and EB reviewed and edited the manuscript. All authors have read and approved the final version of the manuscript.

ORCID

Kenneth Pasmans  <https://orcid.org/0000-0003-4578-2395>

Ruth C. R. Meex  <https://orcid.org/0000-0002-7247-9191>

Luc J. C. van Loon  <https://orcid.org/0000-0002-6768-9231>

Ellen E. Blaak  <https://orcid.org/0000-0002-2496-3464>

REFERENCES

- Kim MK, Han K, Park YM, et al. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. *Circulation*. 2018;138(23):2627-2637. doi:10.1161/CIRCULATIONAHA.118.034978
- Jang JY, Moon S, Cho S, Cho KH, Oh CM. Visit-to-visit HbA1c and glucose variability and the risks of macrovascular and microvascular events in the general population. *Sci Rep*. 2019;9(1):1374. doi:10.1038/s41598-018-37834-7
- Blaak EE, Antoine JM, Benton D, et al. Impact of postprandial glycaemia on health and prevention of disease. *Obes Rev*. 2012;13(10):923-984. doi:10.1111/j.1467-789X.2012.01011.x
- Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. *Lancet*. 2012;379(9833):2243-2251. doi:10.1016/S0140-6736(12)60525-X
- Alssema M, Ruijgrok C, Blaak EE, et al. Effects of alpha-glucosidase-inhibiting drugs on acute postprandial glucose and insulin responses: a systematic review and meta-analysis. *Nutr Diabetes*. 2021;11(1):11. doi:10.1038/s41387-021-00152-5
- Goldberg RB, Temprosa M, Haffner S, et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. *Diabetes Care*. 2009;32(4):726-732. doi:10.2337/dc08-0494
- Kitabchi AE, Temprosa M, Knowler WC, The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. *Diabetes*. 2005;54(8):2404-2414. doi:10.2337/diabetes.54.8.2404
- van Loon LJ, Saris WH, Verhagen H, Wagenmakers AJ. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *Am J Clin Nutr*. 2000;72(1):96-105. doi:10.1093/ajcn/72.1.96
- van Loon LJ, Kruijshoop M, Menheere PP, Wagenmakers AJ, Saris WH, Keizer HA. Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. *Diabetes Care*. 2003;26(3):625-630. doi:10.2337/diacare.26.3.625
- Kim IY, Suh SH, Lee IK, Wolfe RR. Applications of stable, non-radioactive isotope tracers in in vivo human metabolic research. *Exp Mol Med*. 2016;48(1):e203. doi:10.1038/emm.2015.97
- Bruce CR, Hamley S, Ang T, Howlett KF, Shaw CS, Kowalski GM. Translating glucose tolerance data from mice to humans: Insights from stable isotope labelled glucose tolerance tests. *Mol Metab*. 2021;53:101281. doi:10.1016/j.molmet.2021.101281
- Eelderink C, Noort MWJ, Sozer N, et al. Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men. *Eur J Nutr*. 2017;56(3):1063-1076. doi:10.1007/s00394-016-1156-6
- Pasmans K, Meex RCR, Trommelen J, et al. L-arabinose co-ingestion delays glucose absorption derived from sucrose in healthy men and women: a double-blind, randomised crossover trial. *Br J Nutr*. 2021;1-10. doi:10.1017/S0007114521004153
- Scientific Advisory Committee on Nutrition. Carbohydrates and Health. London, England; 2015.
- Augustin LS, Kendall CW, Jenkins DJ, et al. Glycemic index, glycemic load and glycemic response: an International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC). *Nutr Metab Cardiovasc Dis*. 2015;25(9):795-815. doi:10.1016/j.numecd.2015.05.005
- Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet*. 2019;393(10170):434-445. doi:10.1016/S0140-6736(18)31809-9

17. Zafar MI, Mills KE, Zheng J, et al. Low-glycemic index diets as an intervention for diabetes: a systematic review and meta-analysis. *Am J Clin Nutr*. 2019;110(4):891-902. doi:10.1093/ajcn/nqz149
18. Livesey G, Taylor R, Livesey HF, et al. Dietary glycemic index and load and the risk of type 2 diabetes: assessment of causal relations. *Nutrients*. 2019;11(6):1436. doi:10.3390/nu11061436
19. Ojo O, Ojo OO, Adebowale F, Wang XH. The effect of dietary glycaemic index on glycaemia in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Nutrients*. 2018;10(3):373. doi:10.3390/nu10030373
20. van Bakel MM, Slimani N, Feskens EJ, et al. Methodological challenges in the application of the glycemic index in epidemiological studies using data from the European Prospective Investigation into Cancer and Nutrition. *J Nutr*. 2009;139(3):568-575. doi:10.3945/jn.108.097121
21. Brouwer-Brolsma EM, Berendsen AAM, Sluik D, et al. The glycaemic index-food-frequency questionnaire: development and validation of a food frequency questionnaire designed to estimate the dietary intake of glycaemic index and glycaemic load: an effort by the PREVIEW Consortium. *Nutrients*. 2018;11(1):13. doi:10.3390/nu11010013
22. Ruijgrok C, Blaak EE, Egli L, et al. Reducing postprandial glucose in dietary intervention studies and the magnitude of the effect on diabetes-related risk factors: a systematic review and meta-analysis. *Eur J Nutr*. 2020;60(1):259-273. doi:10.1007/s00394-020-02240-1
23. Rodrigues N, Peng M, Oey I, Venn BJ. Glycaemic, uricaemic and blood pressure response to beverages with partial fructose replacement of sucrose. *Eur J Clin Nutr*. 2018;72(12):1717-1723. doi:10.1038/s41430-018-0134-x
24. Pang MD, Goossens GH, Blaak EE. The Impact of artificial sweeteners on body weight control and glucose homeostasis. *Front Nutr*. 2020;7:598340. doi:10.3389/fnut.2020.598340
25. O'Connor D, Pang M, Castelnuovo G, et al. A rational review on the effects of sweeteners and sweetness enhancers on appetite, food reward and metabolic/adiposity outcomes in adults. *Food Funct*. 2021;12(2):442-465. doi:10.1039/D0FO02424D
26. van Can JG, Ijzerman TH, van Loon LJ, Brouns F, Blaak EE. Reduced glycaemic and insulinaemic responses following trehalose ingestion: implications for postprandial substrate use. *Br J Nutr*. 2009;102(10):1395-1399. doi:10.1017/S000711450999050X
27. Yoshizane C, Mizote A, Yamada M, et al. Glycemic, insulinemic and incretin responses after oral trehalose ingestion in healthy subjects. *Nutr J*. 2017;16(1):9. doi:10.1186/s12937-017-0233-x
28. van Can JG, van Loon LJ, Brouns F, Blaak EE. Reduced glycaemic and insulinaemic responses following trehalose and isomaltulose ingestion: implications for postprandial substrate use in impaired glucose-tolerant subjects. *Br J Nutr*. 2012;108(7):1210-1217. doi:10.1017/S0007114511006714
29. van Can JG, Ijzerman TH, van Loon LJ, Brouns F, Blaak EE. Reduced glycaemic and insulinaemic responses following isomaltulose ingestion: implications for postprandial substrate use. *Br J Nutr*. 2009;102(10):1408-1413. doi:10.1017/S0007114509990687
30. Lina BA, Jonker D, Kozianowski G. Isomaltulose (Palatinose): a review of biological and toxicological studies. *Food Chem Toxicol*. 2002;40(10):1375-1381. doi:10.1016/S0278-6915(02)00105-9
31. Henry CJ, Kaur B, Quek RYC, Camps SG. A low glycaemic index diet incorporating isomaltulose is associated with lower glycaemic response and variability, and promotes fat oxidation in Asians. *Nutrients*. 2017;9(5):473. doi:10.3390/nu9050473
32. Suraphad P, Suklaew PO, Ngamukote S, Adisakwattana S, Mäkynen K. The effect of isomaltulose together with green tea on glycemic response and antioxidant capacity: a single-blind, crossover study in healthy subjects. *Nutrients*. 2017;9(5):464. doi:10.3390/nu9050464
33. Tan WS, Tan SY, Henry CJ. Ethnic variability in glycemic response to sucrose and isomaltulose. *Nutrients*. 2017;9(4):347. doi:10.3390/nu9040347
34. Rogers PJ, Appleton KM. The effects of low-calorie sweeteners on energy intake and body weight: a systematic review and meta-analyses of sustained intervention studies. *Int J Obes (Lond)*. 2021;45(3):464-478. doi:10.1038/s41366-020-00704-2
35. Suez J, Korem T, Zeevi D, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. *Nature*. 2014;514(7521):181-186. doi:10.1038/nature13793
36. Lohner S, Kuellenberg de Gaudry D, Toews I, Ferenci T, Meerpohl JJ. Non-nutritive sweeteners for diabetes mellitus. *Cochrane Database Syst Rev*. 2020;5(5):Cd012885. doi:10.1002/14651858.CD012885.pub2
37. Hardy DS, Garvin JT, Xu H. Carbohydrate quality, glycemic index, glycemic load and cardiometabolic risks in the US, Europe and Asia: a dose-response meta-analysis. *Nutr Metab Cardiovasc Dis*. 2020;30(6):853-871. doi:10.1016/j.numecd.2019.12.050
38. Reynolds AN, Akerman AP, Mann J. Dietary fibre and whole grains in diabetes management: systematic review and meta-analyses. *PLoS Med*. 2020;17(3):e1003053. doi:10.1371/journal.pmed.1003053
39. Stephen AM, Champ MM, Cloran SJ, et al. Dietary fibre in Europe: current state of knowledge on definitions, sources, recommendations, intakes and relationships to health. *Nutr Res Rev*. 2017;30(2):149-190. doi:10.1017/S095442241700004X
40. Tieri M, Ghelfi F, Vitale M, et al. Whole grain consumption and human health: an umbrella review of observational studies. *Int J Food Sci Nutr*. 2020;71(6):668-677. doi:10.1080/09637486.2020.1715354
41. Blaak EE, Riccardi G, Cho L. Carbohydrates: separating fact from fiction. *Atherosclerosis*. 2021;328:114-123. doi:10.1016/j.atherosclerosis.2021.03.025
42. Chutkan R, Fahey G, Wright WL, McRorie J. Viscous versus non-viscous soluble fiber supplements: mechanisms and evidence for fiber-specific health benefits. *J Am Acad Nurse Pract*. 2012;24(8):476-487. doi:10.1111/j.1745-7599.2012.00758.x
43. McRorie JW Jr, McKeown NM. Understanding the physics of functional fibers in the gastrointestinal tract: an evidence-based approach to resolving enduring misconceptions about insoluble and soluble fiber. *J Acad Nutr Diet*. 2017;117(2):251-264. doi:10.1016/j.jand.2016.09.021
44. Xie Y, Gou L, Peng M, Zheng J, Chen L. Effects of soluble fiber supplementation on glycemic control in adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. *Clin Nutr*. 2021;40(4):1800-1810. doi:10.1016/j.clnu.2020.10.032
45. Weickert MO, Pfeiffer AFH. Impact of dietary fiber consumption on insulin resistance and the prevention of type 2 diabetes. *J Nutr*. 2018;148(1):7-12. doi:10.1093/jn/nxx008
46. The InterAct Consortium. Dietary fibre and incidence of type 2 diabetes in eight European countries: the EPIC-InterAct Study and a meta-analysis of prospective studies. *Diabetologia*. 2015;58(7):1394-1408. doi:10.1007/s00125-015-3585-9
47. Cassidy YM, McSorley EM, Allsopp PJ. Effect of soluble dietary fibre on postprandial blood glucose response and its potential as a functional food ingredient. *J Funct Foods*. 2018;46:423-439. doi:10.1016/j.jff.2018.05.019
48. Ojo O, Feng QQ, Ojo OO, Wang XH. The role of dietary fibre in modulating gut microbiota dysbiosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. *Nutrients*. 2020;12(11):3239. doi:10.3390/nu12113239
49. Ojo O, Ojo OO, Zand N, Wang X. The effect of dietary fibre on gut microbiota, lipid profile, and inflammatory markers in patients with type 2 diabetes: a systematic review and meta-analysis of

- randomised controlled trials. *Nutrients*. 2021;13(6):1805. doi:[10.3390/nu13061805](https://doi.org/10.3390/nu13061805)
50. Russell WR, Baka A, Bjorck I, et al. Impact of diet composition on blood glucose regulation. *Crit Rev Food Sci Nutr*. 2016;56(4):541-590. doi:[10.1080/10408398.2013.792772](https://doi.org/10.1080/10408398.2013.792772)
 51. Wang L, Yang H, Huang H, et al. Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose-response meta-analysis of 33 randomized controlled trials. *J Transl Med*. 2019;17(1):410. doi:[10.1186/s12967-019-02159-0](https://doi.org/10.1186/s12967-019-02159-0)
 52. Vandeputte D, Falony G, Vieira-Silva S, et al. Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. *Gut*. 2017;66(11):1968-1974. doi:[10.1136/gutjnl-2016-313271](https://doi.org/10.1136/gutjnl-2016-313271)
 53. Lightowler H, Thondre S, Holz A, Theis S. Replacement of glycaemic carbohydrates by inulin-type fructans from chicory (oligofructose, inulin) reduces the postprandial blood glucose and insulin response to foods: report of two double-blind, randomized, controlled trials. *Eur J Nutr*. 2018;57(3):1259-1268. doi:[10.1007/s00394-017-1409-z](https://doi.org/10.1007/s00394-017-1409-z)
 54. Gonlachanvit S, Hsu CW, Boden GH, et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. *Dig Dis Sci*. 2003;48(3):488-497. doi:[10.1023/A:1022528414264](https://doi.org/10.1023/A:1022528414264)
 55. Jones KL, Rigda RS, Butfield MDM, et al. Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. *Diabetes Obes Metab*. 2019;21(5):1158-1167. doi:[10.1111/dom.13633](https://doi.org/10.1111/dom.13633)
 56. Watson LE, Phillips LK, Wu T, et al. A whey/guar "preload" improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: a 12-week, single-blind, randomized, placebo-controlled trial. *Diabetes Obes Metab*. 2019;21(4):930-938. doi:[10.1111/dom.13604](https://doi.org/10.1111/dom.13604)
 57. Horowitz M, Edelbroek MAL, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. *Diabetologia*. 1993;36(9):857-862. doi:[10.1007/BF00400362](https://doi.org/10.1007/BF00400362)
 58. Muller M, Canfora EE, Blaak EE. Gastrointestinal transit time, glucose homeostasis and metabolic health: modulation by dietary fibers. *Nutrients*. 2018;10(3):275. doi:[10.3390/nu10030275](https://doi.org/10.3390/nu10030275)
 59. Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Ghrelin GN. GLP-1, and PYY(3-36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. *Physiol Rev*. 2017;97(1):411-463. doi:[10.1152/physrev.00031.2014](https://doi.org/10.1152/physrev.00031.2014)
 60. Mihai BM, Mihai C, Cijevschi-Prelipcean C, et al. Bidirectional relationship between gastric emptying and plasma glucose control in normoglycemic individuals and diabetic patients. *J Diabetes Res*. 2018;2018:1736959. doi:[10.1155/2018/1736959](https://doi.org/10.1155/2018/1736959)
 61. Wang YT, Mohammed SD, Farmer AD, et al. Regional gastrointestinal transit and pH studied in 215 healthy volunteers using the wireless motility capsule: influence of age, gender, study country and testing protocol. *Aliment Pharmacol Ther*. 2015;42(6):761-772. doi:[10.1111/apt.13329](https://doi.org/10.1111/apt.13329)
 62. Phillips LK, Deane AM, Jones KL, Rayner CK, Horowitz M. Gastric emptying and glycaemia in health and diabetes mellitus. *Nat Rev Endocrinol*. 2015;11(2):112-128. doi:[10.1038/nrendo.2014.202](https://doi.org/10.1038/nrendo.2014.202)
 63. Goyal RK, Cristofaro V, Sullivan MP. Rapid gastric emptying in diabetes mellitus: Pathophysiology and clinical importance. *J Diabetes Complications*. 2019;33(11):107414. doi:[10.1016/j.jdiacomp.2019.107414](https://doi.org/10.1016/j.jdiacomp.2019.107414)
 64. Achour L, Méance S, Briand A. Comparison of gastric emptying of a solid and a liquid nutritional rehabilitation food. *Eur J Clin Nutr*. 2001;55(9):769-772. doi:[10.1038/sj.ejcn.1601221](https://doi.org/10.1038/sj.ejcn.1601221)
 65. Ranawana V, Henry CJK. Liquid and solid carbohydrate foods: comparative effects on glycemic and insulin responses, and satiety. *Int J Food Sci Nutr*. 2011;62(1):71-81. doi:[10.3109/09637486.2010.520011](https://doi.org/10.3109/09637486.2010.520011)
 66. Peters HPF, Ravestein P, van der Hijden HTWM, Boers HM, Mela DJ. Effect of carbohydrate digestibility on appetite and its relationship to postprandial blood glucose and insulin levels. *Eur J Clin Nutr*. 2011;65(1):47-54. doi:[10.1038/ejcn.2010.189](https://doi.org/10.1038/ejcn.2010.189)
 67. Collier G, O'Dea K. The effect of coingestion of fat on the glucose, insulin, and gastric inhibitory polypeptide responses to carbohydrate and protein. *Am J Clin Nutr*. 1983;37(6):941-944. doi:[10.1093/ajcn/37.6.941](https://doi.org/10.1093/ajcn/37.6.941)
 68. Collier G, McLean A, O'Dea K. Effect of co-ingestion of fat on the metabolic responses to slowly and rapidly absorbed carbohydrates. *Diabetologia*. 1984;26(1):50-54. doi:[10.1007/BF00252263](https://doi.org/10.1007/BF00252263)
 69. Estrich D, Ravnik A, Schlierf G, Fukayama G, Kinsell L. Effects of co-ingestion of fat and protein upon carbohydrate-induced hyperglycemia. *Diabetes*. 1967;16(4):232-237. doi:[10.2337/diab.16.4.232](https://doi.org/10.2337/diab.16.4.232)
 70. Gentilcore D, Chaikomin R, Jones KL, et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. *J Clin Endocrinol Metab*. 2006;91(6):2062-2067. doi:[10.1210/jc.2005-2644](https://doi.org/10.1210/jc.2005-2644)
 71. Ma J, Stevens JE, Cukier K, et al. Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. *Diabetes Care*. 2009;32(9):1600-1602. doi:[10.2337/dc09-0723](https://doi.org/10.2337/dc09-0723)
 72. Yu K, Ke MY, Li WH, Zhang SQ, Fang XC. The impact of soluble dietary fibre on gastric emptying, postprandial blood glucose and insulin in patients with type 2 diabetes. *Asia Pac J Clin Nutr*. 2014;23(2):210-218.
 73. Boers HM, van Dijk TH, Hiemstra H, et al. Effect of fibre additions to flatbread flour mixes on glucose kinetics: a randomised controlled trial. *Br J Nutr*. 2017;118(10):777-787. doi:[10.1017/S0007114517002781](https://doi.org/10.1017/S0007114517002781)
 74. Wolever TMS, Tosh SM, Spruill SE, et al. Increasing oat β -glucan viscosity in a breakfast meal slows gastric emptying and reduces glycemic and insulinemic responses but has no effect on appetite, food intake, or plasma ghrelin and PYY responses in healthy humans: a randomized, placebo-controlled, crossover trial. *Am J Clin Nutr*. 2020;111(2):319-328. doi:[10.1093/ajcn/nqz285](https://doi.org/10.1093/ajcn/nqz285)
 75. Zurbau A, Noronha JC, Khan TA, Sievenpiper JL, Wolever TMS. The effect of oat β -glucan on postprandial blood glucose and insulin responses: a systematic review and meta-analysis. *Eur J Clin Nutr*. 2021;5(Supplement_2):533. doi:[10.1093/cdn/nzab041_048](https://doi.org/10.1093/cdn/nzab041_048)
 76. Bergmann JF, Chassany O, Petit A, Triki R, Caulin C, Segrestaa JM. Correlation between echographic gastric emptying and appetite: influence of psyllium. *Gut*. 1992;33(8):1042-1043.
 77. Karhunen LJ, Juvonen KR, Flander SM, et al. A psyllium fiber-enriched meal strongly attenuates postprandial gastrointestinal peptide release in healthy young adults. *J Nutr*. 2010;140(4):737-744. doi:[10.3945/jn.109.115436](https://doi.org/10.3945/jn.109.115436)
 78. Xiao Z, Chen H, Zhang Y, et al. The effect of psyllium consumption on weight, body mass index, lipid profile, and glucose metabolism in diabetic patients: a systematic review and dose-response meta-analysis of randomized controlled trials. *Phytother Res*. 2020;34(6):1237-1247. doi:[10.1002/ptr.6609](https://doi.org/10.1002/ptr.6609)
 79. Jovanovski E, Khayyat R, Zurbau A, et al. Should viscous fiber supplements be considered in diabetes control? Results from a systematic review and meta-analysis of randomized controlled trials. *Diabetes Care*. 2019;42(5):755-766. doi:[10.2337/dc18-1126](https://doi.org/10.2337/dc18-1126)
 80. Alskar O, Bagger JI, Roge RM, et al. Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes. *J Clin Pharmacol*. 2016;56(3):340-348. doi:[10.1002/jcph.602](https://doi.org/10.1002/jcph.602)
 81. Fadda HM, McConnell EL, Short MD, Basit AW. Meal-induced acceleration of tablet transit through the human small intestine. *Pharm Res*. 2009;26(2):356-360. doi:[10.1007/s11095-008-9749-2](https://doi.org/10.1007/s11095-008-9749-2)

82. Nguyen NQ, Debreceni TL, Burgess JE, et al. Impact of gastric emptying and small intestinal transit on blood glucose, intestinal hormones, glucose absorption in the morbidly obese. *Int J Obes (Lond)*. 2018;42(9):1556-1564. doi:10.1038/s41366-018-0012-6
83. Dashty M. A quick look at biochemistry: carbohydrate metabolism. *Clin Biochem*. 2013;46(15):1339-1352. doi:10.1016/j.clinbiochem.2013.04.027
84. Derosa G, Maffioli P. α -Glucosidase inhibitors and their use in clinical practice. *Arch Med Sci*. 2012;8(5):899-906. doi:10.5114/aoms.2012.31621
85. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. α -Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. *Diabetes Care*. 2005;28(1):154-163. doi:10.2337/diacare.28.1.154
86. Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. *Diabetes Metab Syndr Obes*. 2012;5:357-367. doi:10.2147/DMSO.S28340
87. Kato A, Zhang ZL, Wang HY, et al. Design and synthesis of labystegines, hybrid iminosugars from LAB and calystegine, as inhibitors of intestinal α -glucosidases: binding conformation and interaction for ntSI. *J Org Chem*. 2015;80(9):4501-4515.
88. Kumar S, Narwal S, Kumar V, Prakash O. α -Glucosidase inhibitors from plants: a natural approach to treat diabetes. *Pharmacogn Rev*. 2011;5(9):19-29. doi:10.4103/0973-7847.79096
89. Yin Z, Zhang W, Feng F, Zhang Y, Kang W. α -Glucosidase inhibitors isolated from medicinal plants. *Food Sci Human Wellness*. 2014;3(3):136-174. doi:10.1016/j.fshw.2014.11.003
90. Bell L, Lampion DJ, Butler LT, Williams CM. A study of glycaemic effects following acute anthocyanin-rich blueberry supplementation in healthy young adults. *Food Funct*. 2017;8(9):3104-3110. doi:10.1039/C7FO00724H
91. Ercan P, El SN. Inhibitory effects of bioaccessible anthocyanins and procyanidins from apple, red grape, cinnamon on α -amylase, α -glucosidase and lipase. *Int J Vitam Nutr Res*. 2020;(1-2):1-9. doi:10.1024/0300-9831/a000652
92. Castro-Acosta ML, Smith L, Miller RJ, McCarthy DI, Farrimond JA, Hall WL. Drinks containing anthocyanin-rich blackcurrant extract decrease postprandial blood glucose, insulin and incretin concentrations. *J Nutr Biochem*. 2016;38:154-161. doi:10.1016/j.jnutbio.2016.09.002
93. Kong F, Qin Y, Su Z, Ning Z, Yu S. Optimization of extraction of hypoglycemic ingredients from grape seeds and evaluation of α -glucosidase and α -amylase inhibitory effects in vitro. *J Food Sci*. 2018;83(5):1422-1429. doi:10.1111/1750-3841.14150
94. Seri K, Sanai K, Matsuo N, Kawakubo K, Xue C, Inoue S. L-arabinose selectively inhibits intestinal sucrase in an uncompetitive manner and suppresses glycemic response after sucrose ingestion in animals. *Metab Clin Exp*. 1996;45(11):1368-1374. doi:10.1016/S0026-0495(96)90117-1
95. Shibanuma K, Degawa Y, Houda K. Determination of the transient period of the EIS complex and investigation of the suppression of blood glucose levels by L-arabinose in healthy adults. *Eur J Nutr*. 2011;50(6):447-453. doi:10.1007/s00394-010-0154-3
96. Krog-Mikkelsen I, Hels O, Tetens I, Holst JJ, Andersen JR, Bukhave K. The effects of L-arabinose on intestinal sucrase activity: dose-response studies in vitro and in humans. *Am J Clin Nutr*. 2011;94(2):472-478. doi:10.3945/ajcn.111.014225
97. Inoue S, Sanai K, Seri K. Effect of L-arabinose on blood glucose level after ingestion of sucrose-containing food in human. *Nippon Eiyo Shokuryo Gakkaishi*. 2000;53(6):243-247. doi:10.4327/jsnfs.53.243
98. Cohen SA. The clinical consequences of sucrase-isomaltase deficiency. *Mol Cellul Pediatr*. 2016;3(1):5. doi:10.1186/s40348-015-0028-0
99. Oku T, Murata-Takenoshita Y, Yamazaki Y, Shimura F, Nakamura S. D-sorbose inhibits disaccharidase activity and demonstrates suppressive action on postprandial blood levels of glucose and insulin in the rat. *Nutr Res (New York, NY)*. 2014;34(11):961-967. doi:10.1016/j.nutres.2014.09.009
100. Oku T, Tanabe K, Ogawa S, Sadamori N, Nakamura S. Similarity of hydrolyzing activity of human and rat small intestinal disaccharidases. *Clin Exp Gastroenterol*. 2011;4:155-161. doi:10.2147/CEG.S19961
101. Sartorius T, Weidner A, Dharsono T, Boulter A, Wilhelm M, Schon C. Postprandial effects of a proprietary milk protein hydrolysate containing bioactive peptides in prediabetic subjects. *Nutrients*. 2019;11(7):1700. doi:10.3390/nu11071700
102. Neyrinck AM, Pachikian B, Taminiou B, et al. Intestinal sucrase as a novel target contributing to the regulation of glycemia by prebiotics. *PLoS ONE*. 2016;11(8):e0160488. doi:10.1371/journal.pone.0160488
103. Ait-Omar A, Monteiro-Sepulveda M, Poitou C, et al. GLUT2 accumulation in enterocyte apical and intracellular membranes: a study in morbidly obese human subjects and ob/ob and high fat-fed mice. *Diabetes*. 2011;60(10):2598-2607. doi:10.2337/db10-1740
104. Johnston K, Sharp P, Clifford M, Morgan L. Dietary polyphenols decrease glucose uptake by human intestinal Caco-2 cells. *FEBS Lett*. 2005;579(7):1653-1657. doi:10.1016/j.febslet.2004.12.099
105. Kwon O, Eck P, Chen S, et al. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. *FASEB j*. 2007;21(2):366-377. doi:10.1096/fj.06-6620com
106. Wang H, Fowler MI, Messenger DJ, et al. Homoisoflavonoids are potent glucose transporter 2 (GLUT2) inhibitors: a potential mechanism for the glucose-lowering properties of *Polygonatum odoratum*. *J Agric Food Chem*. 2018;66(12):3137-3145. doi:10.1021/acs.jafc.8b00107
107. Kerimi A, Gauer JS, Crabbe S, et al. Effect of the flavonoid hesperidin on glucose and fructose transport, sucrase activity and glycaemic response to orange juice in a crossover trial on healthy volunteers. *Br J Nutr*. 2019;121(7):782-792. doi:10.1017/S0007114519000084
108. Castro-Acosta ML, Stone SG, Mok JE, et al. Apple and blackcurrant polyphenol-rich drinks decrease postprandial glucose, insulin and incretin response to a high-carbohydrate meal in healthy men and women. *J Nutr Biochem*. 2017;49:53-62. doi:10.1016/j.jnutbio.2017.07.013
109. Manzano S, Williamson G. Polyphenols and phenolic acids from strawberry and apple decrease glucose uptake and transport by human intestinal Caco-2 cells. *Mol Nutr Food Res*. 2010;54(12):1773-1780. doi:10.1002/mnfr.201000019
110. Alzaid F, Cheung HM, Preedy VR, Sharp PA. Regulation of glucose transporter expression in human intestinal Caco-2 cells following exposure to an anthocyanin-rich berry extract. *PLoS ONE*. 2013;8(11):e78932. doi:10.1371/journal.pone.0078932
111. Pico J, Martínez MM. Unraveling the inhibition of intestinal glucose transport by dietary phenolics: a review. *Curr Pharm des*. 2019;25(32):3418-3433. doi:10.2174/1381612825666191015154326
112. Coe S, Ryan L. Impact of polyphenol-rich sources on acute postprandial glycaemia: a systematic review. *J Nutr Sci*. 2016;5:e24. doi:10.1017/jns.2016.11
113. Most J, Penders J, Lucchesi M, Goossens GH, Blaak EE. Gut microbiota composition in relation to the metabolic response to 12-week combined polyphenol supplementation in overweight men and women. *Eur J Clin Nutr*. 2017;71(9):1040-1045.
114. Most J, Timmers S, Warnke I, et al. Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial. *Am J Clin Nutr*. 2016;104(1):215-227. doi:10.3945/ajcn.115.122937

115. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. *Cell*. 2015;163(5):1079-1094. doi:[10.1016/j.cell.2015.11.001](https://doi.org/10.1016/j.cell.2015.11.001)
116. Mendes-Soares H, Raveh-Sadka T, Azulay S, et al. Model of personalized postprandial glycemic response to food developed for an Israeli cohort predicts responses in Midwestern American individuals. *Am J Clin Nutr*. 2019;110:63-75. doi:[10.1093/ajcn/nqz028](https://doi.org/10.1093/ajcn/nqz028)
117. Mendes-Soares H, Raveh-Sadka T, Azulay S, et al. Assessment of a personalized approach to predicting postprandial glycemic responses to food among individuals without diabetes. *JAMA Netw Open*. 2019;2(2):e188102. doi:[10.1001/jamanetworkopen.2018.8102](https://doi.org/10.1001/jamanetworkopen.2018.8102)
118. Hall H, Perelman D, Breschi A, et al. Glucotypes reveal new patterns of glucose dysregulation. *PLoS Biol*. 2018;16(7):e2005143. doi:[10.1371/journal.pbio.2005143](https://doi.org/10.1371/journal.pbio.2005143)
119. Berry SE, Valdes AM, Drew DA, et al. Human postprandial responses to food and potential for precision nutrition. *Nat Med*. 2020;26(6):964-973. doi:[10.1038/s41591-020-0934-0](https://doi.org/10.1038/s41591-020-0934-0)
120. Halder S, Egli L, De Castro CA, et al. High or low glycemic index (GI) meals at dinner results in greater postprandial glycemia compared with breakfast: a randomized controlled trial. *BMJ Open*. 2020;8(1):e001099. doi:[10.1136/bmjdr-2019-001099](https://doi.org/10.1136/bmjdr-2019-001099)
121. Morgan LM, Shi JW, Hampton SM, Frost G. Effect of meal timing and glycaemic index on glucose control and insulin secretion in healthy volunteers. *Br J Nutr*. 2012;108(7):1286-1291. doi:[10.1017/S0007114511006507](https://doi.org/10.1017/S0007114511006507)
122. Qian J, Scheer F. Circadian system and glucose metabolism: implications for physiology and disease. *Trend Endocrinol Metab*. 2016;27(5):282-293. doi:[10.1016/j.tem.2016.03.005](https://doi.org/10.1016/j.tem.2016.03.005)

How to cite this article: Pasmans K, Meex RCR, van Loon LJC, Blaak EE. Nutritional strategies to attenuate postprandial glycemic response. *Obesity Reviews*. 2022;23(9):e13486. doi:[10.1111/obr.13486](https://doi.org/10.1111/obr.13486)